Zoetis (ZTS) Shares are Up 1.17%

Zoetis (ZTS) : Traders are bullish on Zoetis (ZTS) as it has outperformed the S&P 500 by a margin of 1.23% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.55%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.17% in the last 1 week, and is up 8.06% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Zoetis (NYSE:ZTS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.17 and $49.87 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.26, notching a gain of 0.24% for the day. The total traded volume was 1,308,113 . The stock had closed at $50.14 on the previous day.


The stock has recorded a 20-day Moving Average of 4.13% and the 50-Day Moving Average is 5.68%. Zoetis Inc. is up 3.55% in the last 3-month period. Year-to-Date the stock performance stands at 5.55%.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.